<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362308</url>
  </required_header>
  <id_info>
    <org_study_id>141553</org_study_id>
    <secondary_id>R01DK096994</secondary_id>
    <nct_id>NCT02362308</nct_id>
  </id_info>
  <brief_title>Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas</brief_title>
  <official_title>Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study tests the hypothesis that endogenous aldosterone impairs insulin&#xD;
      secretion and insulin sensitivity in subjects with primary aldosteronism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The week of each study period, subjects will be provided a standard 160mmol/d sodium diet for&#xD;
      6-8 days to control for inter-individual sodium intake.&#xD;
&#xD;
      In period 1, subjects will report after 5 days of controlled sodium diet for a hyperglycemic&#xD;
      clamp study (to measure insulin secretion). Subjects will continue the study diet, and then&#xD;
      return for a hyperinsulinemic-euglycemic clamp study (to measure insulin sensitivity).&#xD;
&#xD;
      After completion of period 1 assessment, subjects will undergo adrenalectomy by our endocrine&#xD;
      surgeons or initiate medical treatment, according to routine clinical care.&#xD;
&#xD;
      In period 2, the investigators will repeat the studies in the same manner as period 1, 3 to&#xD;
      12 months after adrenalectomy or initiation of medical treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Change in Acute Glucose-stimulated Insulin Secretion</measure>
    <time_frame>Change from Baseline vs. 3-12 months after intervention</time_frame>
    <description>measured by hyperglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity Index</measure>
    <time_frame>Change from Baseline vs. 3-12 months after intervention</time_frame>
    <description>measured by hyperinsulinemic-euglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Disposition Index (product of Insulin sensitivity index and acute insulin secretion)</measure>
    <time_frame>Change from Baseline vs. 3-12 months after intervention</time_frame>
    <description>Product of insulin sensitivity and insulin secretion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suppression of Hepatic glucose production</measure>
    <time_frame>Change from Baseline vs. 3-12 months after intervention</time_frame>
    <description>suppression of hepatic glucose production during hyperinsulinemic clamp, determined using glucose tracer</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Urinary exosomal biomarkers</measure>
    <time_frame>Change from Baseline vs. 3-12 months after intervention</time_frame>
    <description>Urinary biomarkers of renal sodium channels and sodium transporters</description>
  </other_outcome>
  <other_outcome>
    <measure>Associative learning Memory testing</measure>
    <time_frame>Change from Baseline vs. 3-12 months after intervention</time_frame>
    <description>Associative learning task matching images and words</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>Adrenalectomy</arm_group_label>
    <description>Subjects will undergo assessment before and after adrenalectomy for treatment of primary aldosteronism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Therapy</arm_group_label>
    <description>Subjects will undergo assessment before and after medical treatment of primary aldosteronism</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adrenalectomy</intervention_name>
    <description>Adrenalectomy for treatment of primary aldosteronism, according to standard of care</description>
    <arm_group_label>Adrenalectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mineralocorticoid receptor antagonist</intervention_name>
    <description>Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care</description>
    <arm_group_label>Medical Therapy</arm_group_label>
    <other_name>spironolactone</other_name>
    <other_name>eplerenone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ambulatory subjects, 18 to 70 years of age, inclusive&#xD;
&#xD;
          2. For female subjects, the following conditions must be met:&#xD;
&#xD;
               -  postmenopausal status for at least 1 year, or&#xD;
&#xD;
               -  status-post surgical sterilization, or&#xD;
&#xD;
               -  if of childbearing potential, utilization of adequate birth control and&#xD;
                  willingness to undergo urine beta-hcg testing on every study day.&#xD;
&#xD;
          3. Primary aldosteronism determined by both:&#xD;
&#xD;
               -  Biochemical hyperaldosteronism defined as either:&#xD;
&#xD;
                    1. Plasma aldosterone ≥15 ng/dL&#xD;
&#xD;
                    2. or aldosterone-to-renin ratio of ≥30 if on ACE inhibitor&#xD;
&#xD;
                    3. or aldosterone-to-renin ratio of ≥40 in absence of an ACE inhibitor&#xD;
&#xD;
               -  Positive suppression test defined as either:&#xD;
&#xD;
                    1. failure to suppress aldosterone to &lt;7ng/dL after intravenous 0.9% saline&#xD;
                       infusion over 2 hours&#xD;
&#xD;
                    2. failure to suppress 24-hour urinary aldosterone excretion to &lt;12 µcg with&#xD;
                       simultaneously documented urine sodium excretion &gt;200 mmol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Subjects presenting with any of the following will not be included in the study:&#xD;
&#xD;
          1. Previously diagnosed type 1 Diabetes&#xD;
&#xD;
          2. Type II Diabetes, as defined by ADA criteria:&#xD;
&#xD;
               -  Hemoglobin A1C ≥6.5%&#xD;
&#xD;
               -  Fasting plasma glucose ≥126mg/dl (7.0mmol/l)&#xD;
&#xD;
               -  2-hour 75g oral glucose tolerance test (OGTT) plasma glucose ≥200mg/dl (11.1&#xD;
                  mmol/l) d. Current treatment with anti-diabetic medication(s)&#xD;
&#xD;
          3. Impaired renal function [estimated glomerular filtration rate (eGFR) of &lt;30ml/min] as&#xD;
             determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation,&#xD;
             where serum creatinine (Scr) is expressed in mg/dl and age in years.&#xD;
&#xD;
          4. Prior allergies to medications used in the study protocol (e.g. L-arginine, potassium&#xD;
             chloride, insulin), or to drugs within the same class.&#xD;
&#xD;
          5. Screening plasma potassium &gt;5.5 mmol/L or sodium &lt;135 mmol/L&#xD;
&#xD;
          6. Cardiovascular disease such as recent (&lt;6 months) myocardial infarction, presence of&#xD;
             angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy&#xD;
             acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart&#xD;
             block, mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy&#xD;
&#xD;
          7. Breast-feeding&#xD;
&#xD;
          8. Treatment with anticoagulants&#xD;
&#xD;
          9. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or&#xD;
             transient ischemic attack&#xD;
&#xD;
         10. History or presence of immunological or hematological disorders&#xD;
&#xD;
         11. Diagnosis of asthma requiring use of inhaled beta agonist &gt;1 time per week&#xD;
&#xD;
         12. Clinically significant gastrointestinal impairment that could interfere with drug&#xD;
             absorption&#xD;
&#xD;
         13. Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine amino&#xD;
             transaminase (ALT) &gt;2.0 x upper limit of normal range]&#xD;
&#xD;
         14. Hematocrit &lt;35%&#xD;
&#xD;
         15. Any underlying or acute disease requiring regular medication which could possibly pose&#xD;
             a threat to the subject or make implementation of the protocol or interpretation of&#xD;
             the study results difficult, such as arthritis treated with non-steroidal&#xD;
             antiinflammatory drugs&#xD;
&#xD;
         16. Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days&#xD;
             in 1 month)&#xD;
&#xD;
         17. Treatment with lithium salts&#xD;
&#xD;
         18. History of alcohol or drug abuse&#xD;
&#xD;
         19. Treatment with any investigational drug in the 1 month preceding the study&#xD;
&#xD;
         20. Mental conditions rendering the subject unable to understand the nature, scope and&#xD;
             possible consequences of the study&#xD;
&#xD;
         21. Inability to comply with the protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M Luther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Luther JM, Wei DS, Ghoshal K, Peng D, Adler GK, Turcu AF, Nian H, Yu C, Solorzano CC, Pozzi A, Brown NJ. Treatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids. Hypertension. 2021 Apr;77(4):1323-1331. doi: 10.1161/HYPERTENSIONAHA.120.14808. Epub 2021 Feb 15.</citation>
    <PMID>33583202</PMID>
  </results_reference>
  <results_reference>
    <citation>Adler GK, Murray GR, Turcu AF, Nian H, Yu C, Solorzano CC, Manning R, Peng D, Luther JM. Primary Aldosteronism Decreases Insulin Secretion and Increases Insulin Clearance in Humans. Hypertension. 2020 May;75(5):1251-1259. doi: 10.1161/HYPERTENSIONAHA.119.13922. Epub 2020 Mar 16.</citation>
    <PMID>32172621</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2015</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>James Matt Luther</investigator_full_name>
    <investigator_title>James M Luther MD, MSCI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

